CYTK (STOCKS)
Cytokinetics Inc.
$71.220000
+1.070000 (+1.53%)
Prev close: $70.150000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Robert I. Blum
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8,875.81M
- Employees
- 498
- P/E (TTM)
- -10.43
- P/B (TTM)
- -10.73
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
18
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.67 | $-1.69 | +0.0159 | +0.94% |
|
Dec 2025 (Q4)
|
$-1.50 | $-1.49 | -0.0144 | -0.97% |
|
Sep 2025 (Q3)
|
$-2.55 | $-1.61 | -0.9385 | -58.24% |
|
Jun 2025 (Q2)
|
$-1.12 | $-1.41 | +0.2850 | +20.28% |
Financial Statements
| Revenues | $105.82M |
| Benefits Costs and Expenses | $426.17M |
| Costs And Expenses | $773.14M |
| Nonoperating Income/Loss | $45.74M |
| Operating Expenses | $746.06M |
| Research and Development | $411.71M |
| Other Operating Expenses | $229.45M |
| Operating Income/Loss | -$640.25M |
| Income/Loss From Continuing Operations After Tax | -$829.61M |
| Income/Loss From Continuing Operations Before Tax | -$521.50M |
| Net Income/Loss | -$829.61M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$829.61M |
| Net Income/Loss Available To Common Stockholders, Basic | -$829.61M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$6.84 |
| Diluted Earnings Per Share | -$6.84 |
| Basic Average Shares | 363,498 |
| Diluted Average Shares | 363,498 |
| Assets | $1.27B |
| Current Assets | $839.47M |
| Cash | $1.10B |
| Inventory | $154.00K |
| Noncurrent Assets | $434.01M |
| Fixed Assets | $82.44M |
| Other Non-current Assets | $351.58M |
| Liabilities | $2.10B |
| Current Liabilities | $199.19M |
| Accounts Payable | $24.71M |
| Wages | $27.36M |
| Other Current Liabilities | $147.12M |
| Noncurrent Liabilities | $1.90B |
| Equity | -$826.57M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$826.57M |
| Liabilities And Equity | $1.27B |
| Net Cash Flow From Operating Activities | -$523.85M |
| Net Cash Flow From Operating Activities, Continuing | -$523.85M |
| Net Cash Flow From Investing Activities | $56.20M |
| Net Cash Flow From Investing Activities, Continuing | $56.20M |
| Net Cash Flow From Financing Activities | $527.47M |
| Net Cash Flow From Financing Activities, Continuing | $527.47M |
| Exchange Gains/Losses | -$928.00K |
| Net Cash Flow | $58.90M |
| Net Cash Flow, Continuing | $59.83M |
| Comprehensive Income/Loss | -$831.06M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$832.77M |
| Other Comprehensive Income/Loss | -$307.63M |